Cariprazine

Cariprazine
Clinical data
Pronunciation	/kəˈrɪprəˌziːn/
Trade names	Vraylar, Reagila, Symvenu
Other names	RGH-188
AHFS/Drugs.com	Monograph
License data	US DailyMed: Cariprazine; US FDA: Cariprazine;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
Drug class	Atypical antipsychotic
ATC code	N05AX15 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	High
Protein binding	91–97%
Metabolism	Liver via CYP3A4 and to a lesser extent CYP2D6
Metabolites	desmethylcariprazine, didesmethylcariprazine
Elimination half-life	2–4 days for parent drug, and 1–3 weeks for active metabolites
Excretion	Urine (21%), bile
Identifiers
	IUPAC name N'-[trans-4-[2-[4-(2,3-Dichlorophenyl)-1-piperazinyl]ethyl]cyclohexyl]-N,N-dimethylurea;
CAS Number	839712-12-8;
PubChem CID	11154555;
IUPHAR/BPS	7671;
DrugBank	DB06016;
ChemSpider	25999972;
UNII	F6RJL8B278;
KEGG	D09997; as HCl: D09876;
ChEBI	CHEBI:90933;
ChEMBL	ChEMBL2028019;
CompTox Dashboard (EPA)	DTXSID80232867 ;
Chemical and physical data
Formula	C21H32Cl2N4O
Molar mass	427.41 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1;
	InChI InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)/t16-,17- ; Key:KPWSJANDNDDRMB-QAQDUYKDSA-N ;

Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, which is used in the treatment of schizophrenia and bipolar disorder. It is also prescribed as an add-on treatment for bipolar depression and major depressive disorder. Cariprazine acts primarily as a D₃ and D₂ receptor partial agonist, with a preference for the D₃ receptor. It is a partial agonist at the serotonin 5-HT_1A receptor and acts as an antagonist at 5-HT_2B and 5-HT_2A receptors. It is taken by mouth. The most prevalent side effects include nausea, mild sedation, fatigue, and dizziness. At higher dosages, there is an increased risk for restlessness, insomnia, and tremors.

Cariprazine was approved for medical use in the United States in September 2015. It was approved as a generic medication in 2022, but is covered by patents until 2029. Cariprazine was approved by the TGA for use in Australia in 2020. As of 2025, the cost of Cariprazine is generally around $50.00USD, $30.60AUD on the PBS and £80.36 in the UK when on the NHS.